{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:17:15Z","timestamp":1783073835491,"version":"3.54.6"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12307-7","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:33:22Z","timestamp":1783071202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TYK2 signaling as a molecular bridge between cytokine storm and chronic inflammation: therapeutic implications of deucravacitinib"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6645-7152","authenticated-orcid":false,"given":"Ankit","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendra Singh","family":"Ashawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar Deep","family":"Ankalgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"12307_CR1","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1126\/SCIENCE.ABI5200","volume":"374","author":"R Medzhitov","year":"2021","unstructured":"Medzhitov R (2021) The spectrum of inflammatory responses. Science 374:1070\u20131075. https:\/\/doi.org\/10.1126\/SCIENCE.ABI5200","journal-title":"Science"},{"key":"12307_CR2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/NRD.2016.39","volume":"15","author":"JN Fullerton","year":"2016","unstructured":"Fullerton JN, Gilroy DW (2016) Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov 15:551\u2013567. https:\/\/doi.org\/10.1038\/NRD.2016.39","journal-title":"Nat Rev Drug Discov"},{"key":"12307_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/J.CELL.2010.02.029","volume":"140","author":"C Nathan","year":"2010","unstructured":"Nathan C, Ding A (2010) Nonresolving inflammation. Cell 140:871\u2013882. https:\/\/doi.org\/10.1016\/J.CELL.2010.02.029","journal-title":"Cell"},{"key":"12307_CR4","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/S41591-019-0675-0","volume":"25","author":"D Furman","year":"2019","unstructured":"Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, Ferrucci L, Gilroy DW, Fasano A, Miller GW, Miller AH, Mantovani A, Weyand CM, Barzilai N, Goronzy JJ, Rando TA, Effros RB, Lucia A, Kleinstreuer N, Slavich GM (2019) Chronic inflammation in the etiology of disease across the life span. Nat Med 25:1822\u20131832. https:\/\/doi.org\/10.1038\/S41591-019-0675-0","journal-title":"Nat Med"},{"key":"12307_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/EJI.201445427","volume":"46","author":"EL Mills","year":"2016","unstructured":"Mills EL, O\u2019Neill LA (2016) Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal. Eur J Immunol 46:13\u201321. https:\/\/doi.org\/10.1002\/EJI.201445427","journal-title":"Eur J Immunol"},{"key":"12307_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/NRI3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14:36\u201349. https:\/\/doi.org\/10.1038\/NRI3581","journal-title":"Nat Rev Immunol"},{"key":"12307_CR7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/NI.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino AV, Kanno Y, O\u2019Shea JJ (2017) Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol 18:374\u2013384. https:\/\/doi.org\/10.1038\/NI.3691","journal-title":"Nat Immunol"},{"key":"12307_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/NRI.2016.125","volume":"17","author":"P Brodin","year":"2017","unstructured":"Brodin P, Davis MM (2017) Human immune system variation. Nat Rev Immunol 17:21\u201329. https:\/\/doi.org\/10.1038\/NRI.2016.125","journal-title":"Nat Rev Immunol"},{"key":"12307_CR9","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/J.CELL.2015.02.010","volume":"160","author":"ME Kotas","year":"2015","unstructured":"Kotas ME, Medzhitov R (2015) Homeostasis, inflammation, and disease susceptibility. Cell 160:816\u2013827. https:\/\/doi.org\/10.1016\/J.CELL.2015.02.010","journal-title":"Cell"},{"key":"12307_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4331\/WJBC.V13.I1.1","volume":"13","author":"R Muromoto","year":"2022","unstructured":"Muromoto R, Oritani K, Matsuda T (2022) Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World J Biol Chem 13:1. https:\/\/doi.org\/10.4331\/WJBC.V13.I1.1","journal-title":"World J Biol Chem"},{"key":"12307_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London England) 395:1033\u20131034. https:\/\/doi.org\/10.1016\/S0140-6736(20)30628-0","journal-title":"Lancet (London England)"},{"key":"12307_CR12","doi-asserted-by":"publisher","first-page":"163819","DOI":"10.3389\/fphar.2015.00286","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S (2015) Advances and challenges of liposome assisted drug delivery. Front Pharmacol 6:163819. https:\/\/doi.org\/10.3389\/fphar.2015.00286","journal-title":"Front Pharmacol"},{"key":"12307_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/S00281-017-0640-2","volume":"39","author":"JR Teijaro","year":"2017","unstructured":"Teijaro JR (2017) Cytokine storms in infectious diseases. Semin Immunopathol 39:501\u2013503. https:\/\/doi.org\/10.1007\/S00281-017-0640-2","journal-title":"Semin Immunopathol"},{"key":"12307_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/ANNUREV-MED-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66:311\u2013328. https:\/\/doi.org\/10.1146\/ANNUREV-MED-051113-024537","journal-title":"Annu Rev Med"},{"key":"12307_CR15","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/S13555-021-00596-8","volume":"11","author":"A Chimalakonda","year":"2021","unstructured":"Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, Patel A, Shen J, Girgis IG, Banerjee S, Throup J (2021) Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1\/2\/3 Inhibitors. Dermatol Ther (Heidelb) 11:1763\u20131776. https:\/\/doi.org\/10.1007\/S13555-021-00596-8","journal-title":"Dermatol Ther (Heidelb)"},{"key":"12307_CR16","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMRA2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH (2020) Cytokine Storm. N Engl J Med 383:2255\u20132273. https:\/\/doi.org\/10.1056\/NEJMRA2026131;WGROUP:STRING:MMS","journal-title":"N Engl J Med"},{"key":"12307_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41577-020-0353-y","volume":"20","author":"M Merad","year":"2020","unstructured":"Merad M, Martin JC (2020) Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 20:448. https:\/\/doi.org\/10.1038\/s41577-020-0353-y","journal-title":"Nat Rev Immunol"},{"key":"12307_CR18","doi-asserted-by":"publisher","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6. https:\/\/doi.org\/10.1101\/CSHPERSPECT.A016295","DOI":"10.1101\/CSHPERSPECT.A016295"},{"key":"12307_CR19","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/SIGTRANS.2017.23;SUBJMETA","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun SC (2017) NF-\u03baB signaling in inflammation. Signal Transduct Target Ther 2:17023. https:\/\/doi.org\/10.1038\/SIGTRANS.2017.23;SUBJMETA","journal-title":"Signal Transduct Target Ther"},{"key":"12307_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/IMR.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello CA (2018) Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev 281:8\u201327. https:\/\/doi.org\/10.1111\/IMR.12621","journal-title":"Immunol Rev"},{"key":"12307_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/S41577-018-0029-Z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv LB (2018) IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol 18:545\u2013558. https:\/\/doi.org\/10.1038\/S41577-018-0029-Z","journal-title":"Nat Rev Immunol"},{"key":"12307_CR22","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","volume":"50","author":"MJ McGeachy","year":"2019","unstructured":"McGeachy MJ, Cua DJ, Gaffen SL (2019) The IL-17 Family of Cytokines in Health and Disease. Immunity 50:892\u2013906. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.021","journal-title":"Immunity"},{"key":"12307_CR23","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/J.IMMUNI.2019.04.018","volume":"50","author":"S Morioka","year":"2019","unstructured":"Morioka S, Mauer\u00f6der C, Ravichandran KS (2019) Living on the edge: Efferocytosis at the interface of homeostasis and pathology. Immunity 50:1149. https:\/\/doi.org\/10.1016\/J.IMMUNI.2019.04.018","journal-title":"Immunity"},{"key":"12307_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/ANNUREV-PHYSIOL-022516-034339","volume":"79","author":"PJ Murray","year":"2017","unstructured":"Murray PJ (2017) Macrophage Polarization. Annu Rev Physiol 79:541\u2013566. https:\/\/doi.org\/10.1146\/ANNUREV-PHYSIOL-022516-034339","journal-title":"Annu Rev Physiol"},{"key":"12307_CR25","doi-asserted-by":"publisher","first-page":"451543","DOI":"10.3389\/FIMMU.2019.01084\/FULL","volume":"10","author":"M Orecchioni","year":"2019","unstructured":"Orecchioni M, Ghosheh Y, Pramod AB, Ley K (2019) Macrophage polarization: Different gene signatures in M1(Lps+) vs. Classically and M2(LPS-) vs. Alternatively activated macrophages. Front Immunol 10:451543. https:\/\/doi.org\/10.3389\/FIMMU.2019.01084\/FULL","journal-title":"Front Immunol"},{"key":"12307_CR26","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/NATURE09447","volume":"467","author":"K Ghoreschi","year":"2010","unstructured":"Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N, Grainger JR, Chen Q, Kanno Y, Watford WT, Sun HW, Eberl G, Shevach EM, Belkaid Y, Cua DJ, Chen W, O\u2019Shea JJ (2010) Generation of pathogenic T(H)17 cells in the absence of TGF-\u03b2 signalling. Nature 467:967\u2013971. https:\/\/doi.org\/10.1038\/NATURE09447","journal-title":"Nature"},{"key":"12307_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.coi.2009.05.021","volume":"21","author":"YK Lee","year":"2009","unstructured":"Lee YK, Mukasa R, Hatton RD, Weaver CT (2009) Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 21:274\u2013280. https:\/\/doi.org\/10.1016\/j.coi.2009.05.021","journal-title":"Curr Opin Immunol"},{"key":"12307_CR28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/ANNUREV.IMMUNOL.021908.132710","volume":"27","author":"T Korn","year":"2009","unstructured":"Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485\u2013517. https:\/\/doi.org\/10.1146\/ANNUREV.IMMUNOL.021908.132710","journal-title":"Annu Rev Immunol"},{"key":"12307_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1126\/SCIENCE.AAF1098","volume":"352","author":"MG Netea","year":"2016","unstructured":"Netea MG, Joosten LAB, Latz E, Mills KHG, Natoli G, Stunnenberg HG, O\u2019Neill LAJ, Xavier RJ (2016) Trained immunity: A program of innate immune memory in health and disease. Science 352:427. https:\/\/doi.org\/10.1126\/SCIENCE.AAF1098","journal-title":"Science"},{"key":"12307_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/S41577-020-0285-6","volume":"20","author":"MG Netea","year":"2020","unstructured":"Netea MG, Dom\u00ednguez-Andr\u00e9s J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, Stabell Benn C, Sun JC, Xavier RJ, Latz E (2020) Defining trained immunity and its role in health and disease. Nat Rev Immunol 20:375\u2013388. https:\/\/doi.org\/10.1038\/S41577-020-0285-6","journal-title":"Nat Rev Immunol"},{"key":"12307_CR31","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/J.CELL.2016.09.034","volume":"167","author":"B Novakovic","year":"2016","unstructured":"Novakovic B, Habibi E, Wang SY, Arts RJW, Davar R, Megchelenbrink W, Kim B, Kuznetsova T, Kox M, Zwaag J, Matarese F, van Heeringen SJ, Janssen-Megens EM, Sharifi N, Wang C, Keramati F, Schoonenberg V, Flicek P, Clarke L, Pickkers P, Heath S, Gut I, Netea MG, Martens JHA, Logie C, Stunnenberg HG (2016) \u03b2-Glucan Reverses the Epigenetic State of LPS-Induced Immunological Tolerance. Cell 167:1354\u20131368e14. https:\/\/doi.org\/10.1016\/J.CELL.2016.09.034","journal-title":"Cell"},{"key":"12307_CR32","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1016\/J.CELREP.2016.11.011","volume":"17","author":"RJW Arts","year":"2016","unstructured":"Arts RJW, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R, Kleinnijenhuis J, Lachmandas E, Gon\u00e7alves LG, Belinha A, Cunha C, Oosting M, Joosten LAB, Matarese G, van Crevel R, Netea MG (2016) Immunometabolic Pathways in BCG-Induced Trained Immunity. Cell Rep 17:2562\u20132571. https:\/\/doi.org\/10.1016\/J.CELREP.2016.11.011","journal-title":"Cell Rep"},{"key":"12307_CR33","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T Cells and Immune Tolerance. Cell 133:775\u2013787. https:\/\/doi.org\/10.1016\/j.cell.2008.05.009","journal-title":"Cell"},{"key":"12307_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/NRI2343","volume":"8","author":"DAA Vignali","year":"2008","unstructured":"Vignali DAA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8:523\u2013532. https:\/\/doi.org\/10.1038\/NRI2343","journal-title":"Nat Rev Immunol"},{"key":"12307_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/ANNUREV.IMMUNOL.25.022106.141623","volume":"30","author":"SZ Josefowicz","year":"2012","unstructured":"Josefowicz SZ, Lu LF, Rudensky AY (2012) Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 30:531\u2013564. https:\/\/doi.org\/10.1146\/ANNUREV.IMMUNOL.25.022106.141623","journal-title":"Annu Rev Immunol"},{"key":"12307_CR36","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/IJMS19030730","volume":"19","author":"GR Lee","year":"2018","unstructured":"Lee GR (2018) The Balance of Th17 versus Treg Cells in Autoimmunity. Int J Mol Sci 19:730. https:\/\/doi.org\/10.3390\/IJMS19030730","journal-title":"Int J Mol Sci"},{"key":"12307_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.molcel.2014.03.030","volume":"54","author":"R Chovatiya","year":"2014","unstructured":"Chovatiya R, Medzhitov R (2014) Stress, inflammation, and defense of homeostasis. Mol Cell 54:281\u2013288. https:\/\/doi.org\/10.1016\/j.molcel.2014.03.030","journal-title":"Mol Cell"},{"key":"12307_CR38","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/S40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM (2017) JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs 77:521\u2013546. https:\/\/doi.org\/10.1007\/S40265-017-0701-9","journal-title":"Drugs"},{"key":"12307_CR39","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Schett G (2017) Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet (London England) 389:2328\u20132337. https:\/\/doi.org\/10.1016\/S0140-6736(17)31472-1","journal-title":"Lancet (London England)"},{"key":"12307_CR40","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.2741\/3908","volume":"16","author":"B Strobl","year":"2011","unstructured":"Strobl B, Stoiber D, Sexl V, Mueller M (2011) Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front Biosci (Landmark Ed 16:3224\u20133232. https:\/\/doi.org\/10.2741\/3908","journal-title":"Front Biosci (Landmark Ed"},{"key":"12307_CR41","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/PRO.3519","volume":"27","author":"R Morris","year":"2018","unstructured":"Morris R, Kershaw NJ, Babon JJ (2018) The molecular details of cytokine signaling via the JAK\/STAT pathway. Protein Sci 27:1984\u20132009. https:\/\/doi.org\/10.1002\/PRO.3519","journal-title":"Protein Sci"},{"key":"12307_CR42","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/ACS.JMEDCHEM.9B00444","volume":"62","author":"ST Wrobleski","year":"2019","unstructured":"Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, Tokarski JS, Strnad J, Zupa-Fernandez A, Cheng L, Shuster D, Gillooly K, Yang X, Heimrich E, McIntyre KW, Chaudhry C, Khan J, Ruzanov M, Tredup J, Mulligan D, Xie D, Sun H, Huang C, D\u2019Arienzo C, Aranibar N, Chiney M, Chimalakonda A, Pitts WJ, Lombardo L, Carter PH, Burke JR, Weinstein DS (2019) Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem 62:8973\u20138995. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.9B00444","journal-title":"J Med Chem"},{"key":"12307_CR43","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/NRD.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 16:843\u2013862. https:\/\/doi.org\/10.1038\/NRD.2017.201","journal-title":"Nat Rev Drug Discov"},{"key":"12307_CR44","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/NM.3895","volume":"21","author":"MWL Teng","year":"2015","unstructured":"Teng MWL, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, Cua DJ (2015) IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 21:719\u2013729. https:\/\/doi.org\/10.1038\/NM.3895","journal-title":"Nat Med"},{"key":"12307_CR45","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/NRI1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375\u2013386. https:\/\/doi.org\/10.1038\/NRI1604","journal-title":"Nat Rev Immunol"},{"key":"12307_CR46","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/J.IMMUNI.2010.05.003","volume":"32","author":"L Durant","year":"2010","unstructured":"Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, Takahashi H, Sun HW, Kanno Y, Powrie F, O\u2019Shea JJ (2010) Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32:605\u2013615. https:\/\/doi.org\/10.1016\/J.IMMUNI.2010.05.003","journal-title":"Immunity"},{"key":"12307_CR47","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/ANNUREV-IMMUNOL-030409-101212","volume":"28","author":"J Zhu","year":"2010","unstructured":"Zhu J, Yamane H, Paul WE (2010) Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 28:445\u2013489. https:\/\/doi.org\/10.1146\/ANNUREV-IMMUNOL-030409-101212","journal-title":"Annu Rev Immunol"},{"key":"12307_CR48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/NRI3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ (2014) The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 14:585\u2013600. https:\/\/doi.org\/10.1038\/NRI3707","journal-title":"Nat Rev Immunol"},{"key":"12307_CR49","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/ANNUREV-IMMUNOL-032713-120231","volume":"32","author":"WM Schneider","year":"2014","unstructured":"Schneider WM, Chevillotte MD, Rice CM (2014) Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32:513\u2013545. https:\/\/doi.org\/10.1146\/ANNUREV-IMMUNOL-032713-120231","journal-title":"Annu Rev Immunol"},{"key":"12307_CR50","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/NRI2093","volume":"7","author":"A Yoshimura","year":"2007","unstructured":"Yoshimura A, Naka T, Kubo M (2007) SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7:454\u2013465. https:\/\/doi.org\/10.1038\/NRI2093","journal-title":"Nat Rev Immunol"},{"key":"12307_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1146\/ANNUREV.IMMUNOL.18.1.143","volume":"18","author":"H Yasukawa","year":"2000","unstructured":"Yasukawa H, Sasaki A, Yoshimura A (2000) Negative regulation of cytokine signaling pathways. Annu Rev Immunol 18:143\u2013164. https:\/\/doi.org\/10.1146\/ANNUREV.IMMUNOL.18.1.143","journal-title":"Annu Rev Immunol"},{"key":"12307_CR52","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/IJMS24043391","volume":"24","author":"L Rusi\u00f1ol","year":"2023","unstructured":"Rusi\u00f1ol L, Puig L (2023) Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. Int J Mol Sci 24:3391. https:\/\/doi.org\/10.3390\/IJMS24043391","journal-title":"Int J Mol Sci"},{"key":"12307_CR53","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/J.CYTO.2015.01.030","volume":"75","author":"L Sun","year":"2015","unstructured":"Sun L, He C, Nair L, Yeung J, Egwuagu CE (2015) Interleukin 12 (IL-12) Family Cytokines: Role in Immune Pathogenesis and Treatment of CNS Autoimmune Disease. Cytokine 75:249. https:\/\/doi.org\/10.1016\/J.CYTO.2015.01.030","journal-title":"Cytokine"},{"key":"12307_CR54","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.2147\/JIR.S380686","volume":"15","author":"L Shang","year":"2022","unstructured":"Shang L, Cao J, Zhao S, Zhang J, He Y (2022) TYK2 in Immune Responses and Treatment of Psoriasis. J Inflamm Res 15:5373. https:\/\/doi.org\/10.2147\/JIR.S380686","journal-title":"J Inflamm Res"},{"key":"12307_CR55","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/INTIMM\/DXT062","volume":"26","author":"M Ishizaki","year":"2014","unstructured":"Ishizaki M, Muromoto R, Akimoto T, Sekine Y, Kon S, Diwan M, Maeda H, Togi S, Shimoda K, Oritani K, Matsuda T (2014) Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol 26:257\u2013267. https:\/\/doi.org\/10.1093\/INTIMM\/DXT062","journal-title":"Int Immunol"},{"key":"12307_CR56","doi-asserted-by":"publisher","unstructured":"Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L, Barber T, Kaur G, Kuttikkatte SB, Leach OA, Desel C, Faergeman SL, Cheeseman J, Neville MJ, Sawcer S, Compston A, Johnson AR, Everett C, Bell JI, Karpe F, Ultsch M, Eigenbrot C, McVean G, Fugger L (2016) Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med 8. https:\/\/doi.org\/10.1126\/SCITRANSLMED.AAG1974","DOI":"10.1126\/SCITRANSLMED.AAG1974"},{"key":"12307_CR57","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/JDV.20553","volume":"39","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Lebwohl M, Warren RB, Sofen H, Morita A, Paul C, Papp KA, Colombo MJ, Scotto J, Vaile J, Zhuo J, Vritzali E, Berger V, Schroeder G, Banerjee S, Tha\u00e7i D, Strober B (2025) Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO\u20101, PSO\u20102 and long\u2010term extension trials. J Eur Acad Dermatology Venereol 39:1336. https:\/\/doi.org\/10.1111\/JDV.20553","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"12307_CR58","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EHS Choy","year":"2001","unstructured":"Choy EHS, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907\u2013916. https:\/\/doi.org\/10.1056\/NEJM200103223441207","journal-title":"N Engl J Med"},{"key":"12307_CR59","doi-asserted-by":"publisher","unstructured":"Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, Li T, Margolick JB, Pawelec G, Leng SX (2021) Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res Rev 65. https:\/\/doi.org\/10.1016\/J.ARR.2020.101205","DOI":"10.1016\/J.ARR.2020.101205"},{"key":"12307_CR60","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/S41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S (2020) An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 26:1636\u20131643. https:\/\/doi.org\/10.1038\/S41591-020-1051-9","journal-title":"Nat Med"},{"key":"12307_CR61","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/J.ABD.2023.10.002","volume":"99","author":"E L\u00f3pez","year":"2024","unstructured":"L\u00f3pez E, Cabrera R, Lecaros C (2024) Targeted therapy for immune mediated skin diseases. What should a dermatologist know? Bras Dermatologia 99:546\u2013567. https:\/\/doi.org\/10.1016\/J.ABD.2023.10.002","journal-title":"Bras Dermatologia"},{"key":"12307_CR62","doi-asserted-by":"publisher","unstructured":"O\u2019Shea JJ, Gadina M, Siegel RM (2019) Cytokines and Cytokine Receptors. Clin Immunol Princ Pract 127\u2013155. https:\/\/doi.org\/10.1016\/B978-0-7020-6896-6.00009-0. .e1","DOI":"10.1016\/B978-0-7020-6896-6.00009-0"},{"key":"12307_CR63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/IJMS19020530","volume":"19","author":"MA Boutet","year":"2018","unstructured":"Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C (2018) Role of the IL-23\/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci 2018 19:19. https:\/\/doi.org\/10.3390\/IJMS19020530","journal-title":"Int J Mol Sci 2018"},{"key":"12307_CR64","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/JIMMUNOL.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG (2018) Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol 201:1605. https:\/\/doi.org\/10.4049\/JIMMUNOL.1800013","journal-title":"J Immunol"},{"key":"12307_CR65","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.4049\/JIMMUNOL.1002795","volume":"192","author":"MK Crow","year":"2014","unstructured":"Crow MK (2014) Type I interferon in the pathogenesis of lupus. J Immunol 192:5459\u20135468. https:\/\/doi.org\/10.4049\/JIMMUNOL.1002795","journal-title":"J Immunol"},{"key":"12307_CR66","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/RHEUMATOLOGY\/KEW431","volume":"56","author":"A Psarras","year":"2017","unstructured":"Psarras A, Emery P, Vital EM (2017) Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford) 56:1662\u20131675. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEW431","journal-title":"Rheumatology (Oxford)"},{"key":"12307_CR67","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/S41590-019-0415-0","volume":"20","author":"MF Neurath","year":"2019","unstructured":"Neurath MF (2019) Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol 20:970\u2013979. https:\/\/doi.org\/10.1038\/S41590-019-0415-0","journal-title":"Nat Immunol"},{"key":"12307_CR68","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/J.IMMUNI.2019.03.017","volume":"50","author":"M Friedrich","year":"2019","unstructured":"Friedrich M, Pohin M, Powrie F (2019) Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. Immunity 50:992\u20131006. https:\/\/doi.org\/10.1016\/J.IMMUNI.2019.03.017","journal-title":"Immunity"},{"key":"12307_CR69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/J.AUTREV.2013.06.004","volume":"13","author":"A Geremia","year":"2014","unstructured":"Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A (2014) Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 13:3\u201310. https:\/\/doi.org\/10.1016\/J.AUTREV.2013.06.004","journal-title":"Autoimmun Rev"},{"key":"12307_CR70","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U (2018) The pathogenesis of psoriatic arthritis. Lancet 391:2273\u20132284. https:\/\/doi.org\/10.1016\/S0140-6736(18)30830-4","journal-title":"Lancet"},{"key":"12307_CR71","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMRA1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205\u20132219. https:\/\/doi.org\/10.1056\/NEJMRA1004965","journal-title":"N Engl J Med"},{"key":"12307_CR72","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMRA1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic Arthritis. N Engl J Med 376:957\u2013970. https:\/\/doi.org\/10.1056\/NEJMRA1505557","journal-title":"N Engl J Med"},{"key":"12307_CR73","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, M\u00f8ller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR (2020) Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 181:1036\u20131045e9. https:\/\/doi.org\/10.1016\/j.cell.2020.04.026","journal-title":"Cell"},{"key":"12307_CR74","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/S12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A (2018) The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol 55:379\u2013390. https:\/\/doi.org\/10.1007\/S12016-018-8702-3","journal-title":"Clin Rev Allergy Immunol"},{"key":"12307_CR75","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/JCPH.1046","volume":"58","author":"C Banfield","year":"2018","unstructured":"Banfield C, Scaramozza M, Zhang W, Kieras E, Page KM, Fensome A, Vincent M, Dowty ME, Goteti K, Winkle PJ, Peeva E (2018) The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2\/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. J Clin Pharmacol 58:434\u2013447. https:\/\/doi.org\/10.1002\/JCPH.1046","journal-title":"J Clin Pharmacol"},{"key":"12307_CR76","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/ACS.JMEDCHEM.9B00444\/SUPPL_FILE\/JM9B00444_SI_002.CSV","volume":"62","author":"ST Wrobleski","year":"2019","unstructured":"Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, Tokarski JS, Strnad J, Zupa-Fernandez A, Cheng L, Shuster D, Gillooly K, Yang X, Heimrich E, McIntyre KW, Chaudhry C, Khan J, Ruzanov M, Tredup J, Mulligan D, Xie D, Sun H, Huang C, D\u2019Arienzo C, Aranibar N, Chiney M, Chimalakonda A, Pitts WJ, Lombardo L, Carter PH, Burke JR, Weinstein DS (2019) Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem 62:8973\u20138995. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.9B00444\/SUPPL_FILE\/JM9B00444_SI_002.CSV","journal-title":"J Med Chem"},{"key":"12307_CR77","doi-asserted-by":"publisher","unstructured":"Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, Zhang Y, Heimrich EM, McIntyre KW, Cunningham MD, Carman JA, Zhou X, Banas D, Chaudhry C, Li S, D\u2019Arienzo C, Chimalakonda A, Yang XX, Xie JH, Pang J, Zhao Q, Rose SM, Huang J, Moslin RM, Wrobleski ST, Weinstein DS, Salter-Cid LM (2019) Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med 11. https:\/\/doi.org\/10.1126\/SCITRANSLMED.AAW1736","DOI":"10.1126\/SCITRANSLMED.AAW1736"},{"key":"12307_CR78","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMOA1806382","volume":"379","author":"K Papp","year":"2018","unstructured":"Papp K, Gordon K, Tha\u00e7i D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S (2018) Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med 379:1313\u20131321. https:\/\/doi.org\/10.1056\/NEJMOA1806382","journal-title":"N Engl J Med"},{"key":"12307_CR79","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1007\/S13555-023-01050-7","volume":"13","author":"S Jing","year":"2023","unstructured":"Jing S, Lin Y, Dockens R, Marchisin D, He B, Girgis IG, Chimalakonda A, Murthy B, Aras U (2023) Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects. Dermatol Ther (Heidelb) 13:3153\u20133164. https:\/\/doi.org\/10.1007\/S13555-023-01050-7","journal-title":"Dermatol Ther (Heidelb)"},{"key":"12307_CR80","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/1346-8138.16740","volume":"50","author":"S Imafuku","year":"2023","unstructured":"Imafuku S, Tada Y, Hippeli L, Banerjee S, Morita A, Ohtsuki M (2023) Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial. J Dermatol 50:588\u2013595. https:\/\/doi.org\/10.1111\/1346-8138.16740","journal-title":"J Dermatol"},{"key":"12307_CR81","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Tha\u00e7i D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A (2023) Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 88:29\u201339. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.002","journal-title":"J Am Acad Dermatol"},{"key":"12307_CR82","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA (2023) Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol 88:40\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2022.08.061","journal-title":"J Am Acad Dermatol"},{"key":"12307_CR83","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/J.JAAD.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind. \u2026 J Am Acad Dermatol 76:418\u2013431. https:\/\/doi.org\/10.1016\/J.JAAD.2016.11.042","journal-title":"\u2026 J Am Acad Dermatol"},{"key":"12307_CR84","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ART.42391\/ABSTRACT","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S (2023) Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 75:242\u2013252. https:\/\/doi.org\/10.1002\/ART.42391\/ABSTRACT","journal-title":"Arthritis Rheumatol"},{"key":"12307_CR85","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar AA, Van Der Heijde D, Behrens F, Kivitz AJ, Neal J, Kim J, Singhal S, Nowak M, Banerjee S (2022) Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis 81:815\u2013822. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221664","journal-title":"Ann Rheum Dis"},{"key":"12307_CR86","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/JAMADERMATOL.2024.4688","volume":"161","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Lebwohl M, Warren RB, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp KA, Kisa RM, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo MJ, Scotto J, Banerjee S, Strober B, Tha\u00e7i D, Blauvelt A (2024) Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials. JAMA Dermatology 161:56. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2024.4688","journal-title":"JAMA Dermatology"},{"key":"12307_CR87","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/S41577-021-00603-1","volume":"21","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Gravallese EM (2021) Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol 21:680\u2013686. https:\/\/doi.org\/10.1038\/S41577-021-00603-1","journal-title":"Nat Rev Immunol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12307-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12307-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12307-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:33:24Z","timestamp":1783071204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12307-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12307"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12307-7","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"11 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1084"}}